Petros Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTPI research report →
Price Chart
About the company
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED).
- CEO
- Fady Boctor
- IPO
- 2020
- Employees
- 3
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on PTPI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $148.30K
- P/E
- 0.00
- Fwd P/E
- 0.01
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.24
- EV/EBITDA
- 1.32
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -147.02%
- ROIC
- -484.80%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-4,641,350
- Net Income
- $1.91M+113.4%
- EPS
- $-1.56+53.3%
- OCF Growth
- -158.7%
- FCF Growth
- -156.3%
- 52W High
- $0.03
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.92
- RSI (14)
- 48
- Avg Volume
- 110.45K
No earnings-call transcripts are available for PTPI yet.
- Free Float
- 68.3%
- Shares Outstanding
- 42.37M
- Float Shares
- 28.93M
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | WEINSTEIN ROBERT | other | 0 |
| Jun 5, 26 | WALKER WAYNE REMELL | other | 375,000 |
| Jun 5, 26 | Boctor Fady | other | 375,000 |
| Jun 5, 26 | Bernstein Bruce | other | 1,875,000 |
| Jun 5, 26 | Silverman Joshua | other | 4,375,000 |
| Jan 2, 26 | Boctor Fady | other | 500,000 |
| Jan 2, 26 | Silverman Joshua | other | 4,375,000 |
| Jan 2, 26 | WALKER WAYNE REMELL | other | 500,000 |
| Jan 2, 26 | Bernstein Bruce | other | 1,875,000 |
| Feb 19, 25 | WALKER WAYNE REMELL | other | 150,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PTPI coverage
Recent articles, reports, and earnings notes.
No research on PTPI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTPI report →Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)
defenseworld.net · Mar 21
Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) vs. Statera Biopharma (NASDAQ:STAB)
defenseworld.net · Dec 3
Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position
accessnewswire.com · Jun 25
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
accessnewswire.com · May 21
Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
accessnewswire.com · May 20
Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
accessnewswire.com · May 6
Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches
accessnewswire.com · May 1
Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms
accessnewswire.com · Apr 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.